1-Methoxy-4-[2,2,2-trichloro-1-ethoxy-1-(4-methoxyphenyl)ethyl]benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Methoxy-4-[2,2,2-trichloro-1-ethoxy-1-(4-methoxyphenyl)ethyl]benzene
• 英文别名: 1-methoxy-4-[2,2,2-trichloro-1-ethoxy-1-(4-methoxyphenyl)ethyl]benzene
• 化学式: C₁₈H₁₉Cl₃O₃
• 分子量: 389.7
• InChiKey: JDOKHFOAKMODSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US20180312502A1

  公开（公告）日：2018-11-01

  The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

  本发明涉及以下一般式（I）的新的N1-和N7-取代的西比利林衍生物，或其药学上可接受的盐和/或溶剂，特别用作药物，特别用作细胞坏死程序的抑制剂。本发明还涉及包含这种化合物的药物组合物以及制备这种化合物的过程。本发明还包括将一般式（I）的化合物用于器官保存的用途。
• Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US10457678B2

  公开（公告）日：2019-10-29

  The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

  本发明涉及以下通式(I)的新的 N1-和 N7-取代的西苯胺衍生物：(I)或其药学上可接受的盐和/或溶液，特别是用作药物，尤其是用作细胞坏死抑制剂。本发明还涉及包含此类化合物的药物组合物以及制备此类化合物的工艺。本发明还包括通式（I）化合物在器官保存方面的用途。
• N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELLULAR NECROPTOSIS
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP3362450B1

  公开（公告）日：2020-07-01
• N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP3362450A1

  公开（公告）日：2018-08-22
• [EN] N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS<br/>[FR] DÉRIVÉS DE SIBIRILINE N1- ET N7-SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'INHIBITEUR DE LA NÉCROPTOSE CELLULAIRE
  申请人：INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)

  公开号：WO2017064216A1

  公开（公告）日：2017-04-20

  The present invention relates to new N1-and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.